tiprankstipranks
Urogen Pharma (DE:UR8)
NASDAQ:UR8
Germany Market
UR8
Urogen Pharma
RESEARCH TOOLSreports

Urogen Pharma (UR8) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

UR8 Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Urogen
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UR8 Stock 12 Month Forecast

Average Price Target

€32.05
▲(80.66% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Urogen Pharma in the last 3 months. The average price target is €32.05 with a high forecast of €39.38 and a low forecast of €15.75. The average price target represents a 80.66% change from the last price of €17.74.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","21":"€21","40":"€40","11.5":"€11.5","30.5":"€30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39.3772446,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€39.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.048701855000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€32.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.75089784,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€15.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,11.5,21,30.5,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.59,24.80440343076923,26.01880686153846,27.233210292307692,28.447613723076923,29.662017153846154,30.87642058461538,32.09082401538461,33.30522744615384,34.519630876923074,35.734034307692305,36.948437738461536,38.16284116923077,{"y":39.3772446,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.59,24.24066937346154,24.89133874692308,25.542008120384615,26.192677493846155,26.843346867307694,27.494016240769234,28.144685614230774,28.79535498769231,29.44602436115385,30.09669373461539,30.747363108076925,31.398032481538465,{"y":32.048701855000004,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.59,22.98699214153846,22.383984283076924,21.780976424615385,21.177968566153847,20.57496070769231,19.97195284923077,19.36894499076923,18.76593713230769,18.162929273846153,17.559921415384615,16.956913556923077,16.35390569846154,{"y":15.75089784,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.385,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€39.38Average Price Target€32.05Lowest Price Target€15.75
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on DE:UR8
Tara Bancroft
TD Cowen
TD Cowen
€30.63
Buy
72.64%
Upside
Reiterated
06/16/26
Bancroft Reiterates Buy on Zusduri Upside and Pipeline Strength, Maintains $35 Price Target
Guggenheim Analyst forecast on DE:UR8
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
€28
Buy
57.84%
Upside
Reiterated
06/03/26
Guggenheim Remains a Buy on Urogen Pharma (URGN)
H.C. Wainwright Analyst forecast on DE:UR8
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€39.38
Buy
121.97%
Upside
Reiterated
06/03/26
UroGen Buy Rating Reiterated as Teva Settlement Extends JELMYTO Exclusivity; $45 Price Target Maintained
Oppenheimer Analyst forecast on DE:UR8
Leland Gershell
Oppenheimer
Oppenheimer
€35
Buy
97.31%
Upside
Reiterated
05/19/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Goldman Sachs Analyst forecast on DE:UR8
Paul Choi
Goldman Sachs
Goldman Sachs
€15.75
Hold
-11.21%
Downside
Reiterated
05/18/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tectonic Therapeutic (NASDAQ: TECX) and Urogen Pharma (NASDAQ: URGN)
Ladenburg Thalmann & Co. Analyst forecast on DE:UR8
Kevin DeGeeter
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
€37.63
Buy
112.10%
Upside
Initiated
05/11/26
UroGen Pharma assumed with a Buy at LadenburgUroGen Pharma assumed with a Buy at Ladenburg
Piper Sandler Analyst forecast on DE:UR8
Kelsey Goodwin
Piper Sandler
Piper Sandler
€35
Buy
97.31%
Upside
Reiterated
04/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on DE:UR8
Amin Makarem
Jefferies
Jefferies
€35
Buy
97.31%
Upside
Initiated
04/09/26
UroGen Pharma initiated with a Buy at JefferiesUroGen Pharma initiated with a Buy at Jefferies
Scotiabank Analyst forecast on DE:UR8
George Farmer
Scotiabank
Scotiabank
€41.13
Buy
131.83%
Upside
Reiterated
08/06/25
Scotiabank Reaffirms Their Buy Rating on Urogen Pharma (URGN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on DE:UR8
Tara Bancroft
TD Cowen
TD Cowen
€30.63
Buy
72.64%
Upside
Reiterated
06/16/26
Bancroft Reiterates Buy on Zusduri Upside and Pipeline Strength, Maintains $35 Price Target
Guggenheim Analyst forecast on DE:UR8
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
€28
Buy
57.84%
Upside
Reiterated
06/03/26
Guggenheim Remains a Buy on Urogen Pharma (URGN)
H.C. Wainwright Analyst forecast on DE:UR8
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€39.38
Buy
121.97%
Upside
Reiterated
06/03/26
UroGen Buy Rating Reiterated as Teva Settlement Extends JELMYTO Exclusivity; $45 Price Target Maintained
Oppenheimer Analyst forecast on DE:UR8
Leland Gershell
Oppenheimer
Oppenheimer
€35
Buy
97.31%
Upside
Reiterated
05/19/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Goldman Sachs Analyst forecast on DE:UR8
Paul Choi
Goldman Sachs
Goldman Sachs
€15.75
Hold
-11.21%
Downside
Reiterated
05/18/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tectonic Therapeutic (NASDAQ: TECX) and Urogen Pharma (NASDAQ: URGN)
Ladenburg Thalmann & Co. Analyst forecast on DE:UR8
Kevin DeGeeter
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
€37.63
Buy
112.10%
Upside
Initiated
05/11/26
UroGen Pharma assumed with a Buy at LadenburgUroGen Pharma assumed with a Buy at Ladenburg
Piper Sandler Analyst forecast on DE:UR8
Kelsey Goodwin
Piper Sandler
Piper Sandler
€35
Buy
97.31%
Upside
Reiterated
04/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on DE:UR8
Amin Makarem
Jefferies
Jefferies
€35
Buy
97.31%
Upside
Initiated
04/09/26
UroGen Pharma initiated with a Buy at JefferiesUroGen Pharma initiated with a Buy at Jefferies
Scotiabank Analyst forecast on DE:UR8
George Farmer
Scotiabank
Scotiabank
€41.13
Buy
131.83%
Upside
Reiterated
08/06/25
Scotiabank Reaffirms Their Buy Rating on Urogen Pharma (URGN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Urogen Pharma

3 Months
Ram SelvarajuH.C. Wainwright
Success Rate
9/15 ratings generated profit
60%
Average Return
-3.29%
Copying Ram Selvaraju's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of -3.29% per trade.
1 Year
Tara BancroftTD Cowen
Success Rate
13/16 ratings generated profit
81%
Average Return
+47.18%
Copying Tara Bancroft's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +47.18% per trade.
2 Years
Tara BancroftTD Cowen
Success Rate
16/16 ratings generated profit
100%
Average Return
+99.32%
Copying Tara Bancroft's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +99.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UR8 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
2
5
9
10
8
Buy
0
0
0
6
8
Hold
0
0
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
5
9
17
17
In the current month, UR8 has received 16 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. UR8 average Analyst price target in the past 3 months is 32.05.
Each month's total comprises the sum of three months' worth of ratings.

UR8 Financial Forecast

UR8 Earnings Forecast

Next quarter’s earnings estimate for UR8 is -€0.26 with a range of -€0.52 to -€0.18. The previous quarter’s EPS was -€0.40. UR8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year UR8 has Performed in-line its overall industry.
Next quarter’s earnings estimate for UR8 is -€0.26 with a range of -€0.52 to -€0.18. The previous quarter’s EPS was -€0.40. UR8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year UR8 has Performed in-line its overall industry.

UR8 Sales Forecast

Next quarter’s sales forecast for UR8 is €52.83M with a range of €48.81M to €57.04M. The previous quarter’s sales results were €43.71M. UR8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year UR8 has Performed in-line its overall industry.
Next quarter’s sales forecast for UR8 is €52.83M with a range of €48.81M to €57.04M. The previous quarter’s sales results were €43.71M. UR8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year UR8 has Performed in-line its overall industry.

UR8 Stock Forecast FAQ

What is DE:UR8’s average 12-month price target, according to analysts?
Based on analyst ratings, Urogen Pharma’s 12-month average price target is 32.05.
    What is DE:UR8’s upside potential, based on the analysts’ average price target?
    Urogen Pharma has 80.66% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Urogen Pharma a Buy, Sell or Hold?
          Urogen Pharma has a consensus rating of Strong Buy, which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Urogen Pharma’s share price target?
            The average share price target for Urogen Pharma is 32.05. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €39.38 ,and the lowest forecast is €15.75. The average share price target represents 80.66% Increase from the current price of €17.74.
              What do analysts say about Urogen Pharma?
              Urogen Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Urogen Pharma?
                To buy shares of DE:UR8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.